Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the pathological response rate in operable breast
cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".